Prevention of hepatocellular carcinoma

New England Journal of Medicine

Volumn 351, Issue 15, 2004, Pages 1567-1570

  Wands, Jack R ^a,b  

^a Liver Research Center Brown University Medical School   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG;

ALCOHOL ABUSE; CANCER PREVENTION; CARCINOGENESIS; CELL TRANSFORMATION; CLINICAL TRIAL; DRUG SAFETY; EDITORIAL; ENVIRONMENTAL EXPOSURE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER INJURY; MORTALITY; PERSISTENT INFECTION; PRIORITY JOURNAL; RISK FACTOR; VIRUS MUTANT; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER NEOPLASMS; MUTATION; VIRUS REPLICATION;

EID: 4744358028     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe048237     Document Type: Editorial

References (14)

1. El-Serag HB, Davila JA, Petersen JN, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-23. [Erratum, Ann Intern Med 2004;140:151.]
2. El-Serag HB, Davila JA, Petersen JN, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-23. [Erratum, Ann Intern Med 2004;140:151.]
3. Tagger A, Donato F, Ribero ML, et al. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Int J Cancer 1999;81:695-9.
4. Moradpour D, Wands JR, Molecular pathogenesis of hepatocellular carcinoma. In: Zakim D, Boyer TD, eds. Hepatology: a textbook of liver disease. 4th ed. Vol. 2. Philadelphia: W.B. Saunders, 2003: 1333-54.
5. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004;350:1118-29.
6. Pollicino T, Squadrito G, Cerenzia G, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004;126:102-10.
7. Liang TJ, Baruch Y, Ben-Porath E, et al. Hepatitis B virus infection in patients with idiopathic liver disease. Hepatology 1991;13: 1044-51.
8. Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001;33:751-7.
9. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Latas A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-51.
10. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
11. Liaw Y-F, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-31.
12. Westland CE, Yang H, Delaney WE IV, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003;38:96-103.
13. Colonno RJ, Genovesi EV, Medina I, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001;184:1236-45.
14. Chang M-H, Chen C-J, Lai M-S, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336:1855-9.